In large part due to COVID-19, interest in telehealth has soared. Companies like emocha have expanded their services from medication adherence monitoring for chronic and infectious diseases to remote symptoms monitoring, in order to meet the market demand for symptom tracking and return-to-work efforts. emocha’s CEO Sebastian Seiguer states, “COVID-19 has forced us to scale to thousands and thousands of patients more than we had before.” Investor funding will be used for the growth of both the emocha team and the accounts they handle. While other similar companies are likely to look into mergers and acquisitions in the near future, emocha is not currently focused on getting acquired, but could potentially work with a larger number of healthcare players beyond digital health companies.

Read the full article from Mergermarket